Erratum: Differential effects of enalapril–felodipine versus enalapril–lercanidipine combination drug treatment on sympathetic nerve traffic and metabolic profile in obesity-related hypertension (Journal of the American Society of Hypertension (2016) 10(3) (244–251) (S1933171116000073) (10.1016/j.jash.2016.01.006));Differential effects of enalapril-felodipine versus enalapril-lercanidipine combination drug treatment on sympathetic nerve traffic and metabolic profile in obesity-related hypertension

Journal of the American Society of Hypertension

Volumn 10, Issue 3, 2016, Pages 244-251

  Seravalle, Gino ^a   Brambilla, Gianmaria ^b   Pizzalla, Daniela Prata ^b   Casati, Anna ^b   Riva, Marta ^b   Cuspidi, Cesare ^b   Bombelli, Michele ^b   Mancia, Giuseppe ^a   Grassi, Guido ^b,c  

^a ISTITUTO AUXOLOGICO ITALIANO   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

^c IRCCS MULTIMEDICA   (Italy)

Author keywords

Combination drug treatment; lercanidipine; obesity related hypertension; sympathetic activity

Indexed keywords

ENALAPRIL; FELODIPINE; LERCANIDIPINE; NORADRENALIN; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADD ON THERAPY; ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; ASSESSMENT OF HUMANS; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; FEMALE; HEADACHE; HEART PALPITATION; HEART RATE; HOMEOSTASIS MODEL ASSESSMENT INDEX; HUMAN; HYPERTENSION; INSULIN SENSITIVITY; MALE; MORNING DOSAGE; MUSCLE SYMPATHETIC NERVE ACTIVITY; MUSCLE SYMPATHETIC NERVE TRAFFIC; MUSCULOSKELETAL SYSTEM PARAMETERS; NORADRENALIN BLOOD LEVEL; OBESITY; PERIPHERAL EDEMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; ADRENERGIC SYSTEM; BLOOD; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPLICATION; DRUG EFFECTS; INSULIN RESISTANCE; METABOLOME; MIDDLE AGED; RANDOMIZATION;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE MONITORING, AMBULATORY; CALCIUM CHANNEL BLOCKERS; CROSS-OVER STUDIES; DIHYDROPYRIDINES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ENALAPRIL; FELODIPINE; FEMALE; HEART RATE; HUMANS; HYPERTENSION; INSULIN RESISTANCE; MALE; METABOLOME; MIDDLE AGED; NOREPINEPHRINE; OBESITY; RANDOM ALLOCATION; SYMPATHETIC NERVOUS SYSTEM;

EID: 84960320408     PISSN: 19331711     EISSN: 18787436     Source Type: Journal    
DOI: 10.1016/j.jash.2017.06.010     Document Type: Erratum

References (34)

1. M.S. Rumantir, M. Vaz, G.L. Jennings, G. Collier, D.M. Kaye, D.R. Seals, and et al. Neural mechanisms in human obesity-related hypertension J Hypertens 17 8 1999 1125 1133
2. G. Grassi, G. Seravalle, R. Dell'Oro, C. Turri, G.B. Bolla, and G. Mancia Adrenergic and reflex abnormalities in obesity-related hypertension Hypertension 36 4 2000 538 542
3. K. Rahmouni, M.L. Correia, W.G. Haynes, and A.L. Mark Obesity-associated hypertension: new insights into mechanisms Hypertension 45 1 2005 9 14
4. M. Esler, N. Straznicky, N. Eikelis, K. Masuo, G. Lambert, and E. Lambert Mechanisms of sympathetic activation in obesity-related hypertension Hypertension 48 5 2006 787 796
5. C. Feldstein, and S. Julius The complex interaction between overweight, obesity and the sympathetic nervous system J Am Soc Hypertens 3 6 2009 353 365
6. G. Mancia, R. Fagard, K. Narkiewicz, J. Redon, A. Zanchetti, M. Bohm, et al. Task Force Members 2013 ESH/ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) Eur Heart J 34 28 2013 2159 2219
7. E. Reisin, and J. Owen Treatment: special conditions. Metabolic syndrome: obesity and the hypertension connection J Am Soc Hypertens 9 2 2015 156 159
8. G. Grassi, A. Mark, and M. Esler The sympathetic nervous system alterations in human hypertension Circ Res 116 6 2015 976 990
9. J.E. Hall, J.M. do Carmo, A.A. da Silva, Z. Wang, and M.E. Hall Obesity-related hypertension: interaction of neurohumoral and renal mechanisms Circ Res 116 6 2015 991 1006
10. G. Mancia, and G. Grassi The autonomic nervous system and hypertension Circ Res 114 11 2014 1804 1811
11. N.B. Schiller, P.M. Shah, M. Crawford, A. DeMaria, R. Devereux, H. Feigenbaum, and et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms J Am Soc Echocardiogr 2 5 1989 358 367
12. S.H. Park, C. Shub, T.P. Nobrega, K.R. Bailey, and J.B. Seward Two-dimensional echocardiographic calculation of left ventricular mass as recommended by the American Society of Echocardiography: correlation with autopsy and M-mode echocardiography J Am Soc Echocardiogr 9 2 1996 119 128
13. G. Grassi, G. Seravalle, C. Turri, G.B. Bolla, and G. Mancia Short- versus long-term effects of different dihydropyridines on sympathetic and baroreflex function in hypertension Hypertension 41 3 2003 558 562
14. P. Hjemdahl, M. Daleskog, and T. Kahan Determination of plasma catecholamines by high performance liquid chromatography with electrochemical detection: comparison with a radioenzymatic method Life Sci 25 2 1979 131 138
15. D.R. Matthews, J.P. Hosker, A.S. Rudenski, B.A. Naylor, D.F. Treacher, and R.C. Turner Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentration in man Diabetologia 28 7 1985 412 419
16. A. Groppelli, S. Omboni, G. Parati, and G. Mancia Evaluation of noninvasive blood pressure monitoring devices Spacelabs 90202 and 90207 versus resting and ambulatory 24-h intraarterial blood pressure Hypertension 20 2 1992 227 232
17. G. Bakris, M. Molitch, A. Hewkin, M. Kipnes, P. Sarafidis, K. Fakouhi, and et al. Differences in glucose tolerance between fixed dose antihypertensive drug combinations in people with metabolic syndrome Diab Care 29 12 2006 2592 2597
18. G. Mancia, and A.L. Mark Arterial baroreflex in humans J.T. Shepherd, F.M. Abboud, Handbook of Physiology: The Cardiovascular System 1983 American Physiological Society Bethesda, MD 755 793
19. P.A. Todd, and D. Faulds Felodipine: a review of the pharmacological and therapeutic use of the extend release formulations in cardiovascular disorders Drugs 44 2 1992 251 277
20. B.P. McGrath, R.W. Watts, and D.B. Elmfeldt Clinical equivalence of two tablet formulations of felodipine: a placebo controlled study of 24-hour blood pressure control and tolerability Eur J Clin Pharmacol 49 3 1995 169 172
21. S. Omboni, and A. Zanchetti Antihypertensive efficacy of lercanidipine at 2.5, 5, and 10 mg in mild-to-moderate essential hypertensives assessed by clinic and ambulatory blood pressure measurements. Multicenter Study Investigators J Hypertens 16 12 1998 1831 1838
22. K.J. McClellan, and B. Jarvis Lercanidipine: a review of its using in hypertension Drugs 60 5 2000 1123 1140
23. J. Inomata, H. Murai, S. Kaneko, T. Hamaoka, T. Ikeda, D. Kobayashi, and et al. Differential effects of azelnidipine and amlodipine on sympathetic nerve activity in patients with primary hypertension J Hypertens 32 9 2014 1898 1904
24. G. Grassi Counteracting the sympathetic nervous system in hypertension Curr Opin Nephrol Hypertens 13 5 2004 513 519
25. P. Raheja, A. Price, Z. Wang, D. Arbique, B. Adams-Huet, R.J. Auchus, and et al. Spironolactone prevents chlorthalidone-induced sympathetic activation and insulin resistance in hypertensive patients Hypertension 60 2 2012 319 325
26. J.A. Dorresteijn, I.M. Schrover, F.L. Visseren, P.G. Scheffer, P.L. Oey, A.H. Danser, and et al. Differential effects of renin-angiotensin system inhibition, sympathoinhibition and blood pressure in obesity-related hypertension: a double-blind, placebo controlled cross-over trial J Hypertens 31 2 2013 393 403
27. K. Shimada, K. Miyauchi, and H. Daida Azelnidipine and glucose tolerance: possible indications and treatment selection for hypertensive patients with metabolic disorders Expert Rev Cardiovasc Ther 13 1 2015 23 31
28. C. De Ciuceis, V. Flati, C. Rossini, A. Rufo, E. Porteri, J. Di Gregorio, and et al. Effect of antihypertensive treatments on insulin signalling in lympho-monocytes of essential hypertensive patients: a pilot study Blood Press 23 6 2014 330 338
29. G. Mancia, A. Coca, I. Chazova, X. Girerd, H. Haller, P. Pauletto, et al. FELT Investigators Effects on office and home blood pressure of the lercanidipine/enalapril combination in patients with stage 2 hypertension: a European randomized controlled trial J Hypertens 32 8 2014 1700 1707
30. A.H. Gradman, N.R. Cutler, P.J. Davis, J.A. Robbins, R.J. Weiss, B.C. Wood, and et al. Long-term efficacy, tolerability and safety of the combination enalapril and felodipine in the treatment of hypertension. Enalapril-Felodipine Factorial Study Group Clin Ther 20 3 1998 527 538
31. P.I. Hair, L.J. Scott, and C.M. Perry Fixed-dose combination Lercanidipine-Enalapril Drugs 67 1 2007 95 106
32. J. De Champlain, M. Karas, P. Nguyen, P. Cartier, R. Wistaff, C.B. Toal, and et al. Different effects of nifedipine and amlodipine on circulating catecholamine levels in essential hypertensive patients J Hypertens 16 11 1998 1357 1369
33. G. Grassi, S. Vailati, G. Bertinieri, G. Seravalle, M.L. Stella, R. Dell'Oro, and et al. Heart rate as marker of sympathetic activity J Hypertens 16 11 1998 1635 1639
34. M.J. Shen, and D.P. Zipes Role of the autonomic nervous system in modulating cardiac arrhythmias Circ Res 114 6 2014 1004 1021